Key Highlights
- Completion of asset purchase agreement: Novo Nordisk acquires Hemophilia A program and gene editing technology.
- Team transition: 2seventy bio team joins Novo Nordisk to advance technology.
- Focus on Abecma: 2seventy bio will concentrate on its BCMA-targeted CAR T cell therapy for multiple myeloma.
Source: Business Wire
Notable Quotes
- “We are pleased to announce the completion of this APA with Novo Nordisk as we believe it will provide the appropriate resources for both the team and the science behind this important program.” — Chip Baird, CEO at 2seventy bio
- “We are devoted to developing therapies with a curative outlook, including our continued development of a next-generation in vivo genome editing program aiming to offer individuals living with Hemophilia A a lifetime free of factor replacement therapy.” — Karina Thorn, Corporate Vice President, Global Nucleic Acid Therapies Research at Novo Nordisk
SoHC's Take
This strategic move marks a significant milestone for 2seventy bio and Novo Nordisk. By transferring the Hemophilia A program and gene editing technology to Novo Nordisk, 2seventy bio ensures that the resources and expertise needed for pioneering therapeutic applications are in place. This acquisition not only strengthens Novo Nordisk’s portfolio in gene editing but also allows 2seventy bio to concentrate on the commercialization and development of Abecma, its promising CAR T cell therapy for multiple myeloma. This focused approach is likely to benefit patients significantly, as both companies leverage their strengths to advance cutting-edge treatments.
